Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for NorovirusGlobeNewsWire • 03/17/23
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15GlobeNewsWire • 03/08/23
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29GlobeNewsWire • 11/22/22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/08/22
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/01/22
3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall StreetThe Motley Fool • 10/25/22
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8GlobeNewsWire • 10/20/22
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine CandidateGlobeNewsWire • 09/01/22
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 TrialGlobeNewsWire • 08/31/22
Vaxart, Inc. (VXRT) CEO Cezar Floroiu on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22